Sorafenib

證據等級: L5

預測適應症: 10 個

Sorafenib: From Renal Cell Carcinoma/Hepatocellular Carcinoma to Liposarcoma

One-Sentence Summary

Sorafenib is a multi-kinase inhibitor originally established for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma. The TxGNN model predicts it may be effective for Liposarcoma, with 2 clinical trials (1 sorafenib-direct) and 8 publications currently supporting this direction, alongside nine other candidate indications of varying evidence strength (including a stronger L1/Phase 3-backed signal for unclassified renal cell carcinoma).

Quick Overview

Item	Content
Original Indication	Renal cell carcinoma / Hepatocellular carcinoma / Differentiated thyroid carcinoma (established global indications; no Fimea license record found in this dataset)
Predicted New Indication	Liposarcoma
TxGNN Prediction Score	99.82%
Evidence Level	L2
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data for sorafenib is not available in the structured field of this evidence pack. Based on well-established pharmacology, sorafenib is a multi-target oral kinase inhibitor that blocks RAF (including wild-type and mutant BRAF), and receptor tyrosine kinases involved in angiogenesis and tumor proliferation — VEGFR-1/2/3, PDGFR-β, FLT3, and c-KIT. This dual RAF/MEK/ERK-pathway and anti-angiogenic activity underlies its proven efficacy in renal cell carcinoma and hepatocellular carcinoma.

Soft tissue sarcomas, including liposarcoma, frequently show activation of the RAS/RAF/MEK/ERK signaling axis and are strongly dependent on tumor neovascularization — the same biological features sorafenib was designed to target. Preclinical work in dedifferentiated liposarcoma xenografts links PTEN down-regulation to a malignant, angiogenesis-dependent phenotype and to sensitivity to PI3K/RAF-pathway inhibition (PMID 23416162), providing a mechanistic bridge from sorafenib's known targets to this tumor type.

This plausibility is reinforced by clinical precedent: sorafenib's anti-angiogenic mechanism is already validated in a closely related, VEGF-driven solid tumor (renal cell carcinoma, see the separately evaluated "unclassified renal cell carcinoma" candidate, which reached L1/S3 evidence with a completed Phase 3 trial of 544 patients). The completed Phase 2 trial in advanced soft tissue sarcoma (NCT00217620, n=51) offers direct, disease-specific supporting evidence, though it has not yet been followed by a confirmatory Phase 3 study specific to liposarcoma.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00217620	Phase 2	Completed	51	Sorafenib (BAY 43-9006) tested directly in advanced soft tissue sarcomas, including liposarcoma subtype; rationale based on blocking tumor-growth enzymes and tumor blood supply. Graded A (direct, same-drug evidence).
NCT02048371	Phase 2	Completed	131	SARC024 blanket protocol studying regorafenib (not sorafenib) across sarcoma subtypes, citing sorafenib's activity in soft tissue sarcoma as rationale. Graded C — different drug, low direct relevance to sorafenib.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21751200	2012	RCT (Phase 2, SWOG S0505)	Cancer	Phase 2 intergroup trial of sorafenib in advanced soft tissue sarcoma, evaluating its multitargeted kinase inhibition (RAF, VEGFR1-3, PDGFR-β, FLT3, c-KIT) in a population with limited therapeutic options.
22987955	2012	Review	Annals of Oncology	Histology-driven review of soft tissue sarcoma treatment; notes trabectedin's high activity specifically in liposarcoma and outlines targeted-therapy rationale by subtype.
24712007	2014	Review	Magyar Onkologia	Subtype-based review of soft tissue sarcoma pharmacotherapy, covering targeted agents alongside conventional cytotoxics.
36003796	2022	Review	Frontiers in Oncology	Reviews patient-derived orthotopic xenograft (PDOX) models identifying effective combination therapies (e.g., with CDK inhibitor palbociclib) for sarcomas.
24554062	2014	Phase 1 trial	Annals of Surgical Oncology	Neoadjuvant conformal radiotherapy plus sorafenib in locally advanced extremity soft tissue sarcoma, based on preclinical synergy between anti-angiogenic therapy and radiotherapy.
18413802	2008	Preclinical	Molecular Cancer Therapeutics	Sorafenib inhibits growth and MAPK signaling in malignant peripheral nerve sheath tumor and dedifferentiated liposarcoma (LS141, DDLS) cell lines, both Ras/Raf pathway-activated tumor types.
23416162	2013	Preclinical (xenograft)	American Journal of Pathology	Novel dedifferentiated liposarcoma xenograft models show PTEN down-regulation as a malignant signature, linking response to PI3K-pathway (and by extension RAF-pathway) inhibition.
25075796	2014	Case report	Anti-Cancer Drugs	Response to trabectedin (not sorafenib) in a synovial sarcoma patient with lung metastases; low direct relevance to sorafenib.

Cytotoxicity

Sorafenib is an antineoplastic agent (multi-kinase inhibitor), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (multi-kinase inhibitor: RAF/MEK/ERK pathway + VEGFR/PDGFR anti-angiogenic activity)
Myelosuppression Risk	No myelosuppression data supplied in this evidence pack. As a class, targeted kinase inhibitors like sorafenib are typically associated with non-hematologic toxicities (hand-foot skin reaction, hypertension, diarrhea) rather than significant bone marrow suppression — please refer to the package insert for confirmed hematologic risk.
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Blood pressure, liver function tests, skin/dermatologic assessment, CBC
Handling Protection	Oral formulation — follow institutional hazardous/antineoplastic drug handling policy for oral kinase inhibitors

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: One completed Phase 2 trial (NCT00217620) directly tests sorafenib in advanced soft tissue sarcoma including liposarcoma, supported by preclinical mechanistic evidence (PTEN/RAF pathway) and a coherent biological rationale, but no confirmatory Phase 3 data exists specific to liposarcoma — consistent with the L2/S2 evidence rating.

To proceed, the following is needed:

TFDA/Fimea package insert warnings, contraindications, and DDI data (currently blocking — DG001)
Confirmed mechanism-of-action documentation from DrugBank (DG002)
A confirmatory Phase 2/3 trial or expanded case series specific to liposarcoma (current direct evidence is a single completed Phase 2 study)
Formal safety monitoring plan given the complete absence of hematologic/toxicity data in this pack
Note: among the 10 candidates evaluated for sorafenib, "unclassified renal cell carcinoma" carries markedly stronger evidence (L1, completed Phase 3, n=544) and may warrant separate, higher-priority evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.